GLP-1 specialist rides wave of interest toward Nasdaq listing

21 November 2023

Just six months after raising $150 million in an upsized series E financing, cardiometabolic specialist Carmot Therapeutics has filed for an initial public offering (IPO).

Founded in 2008, the company has attracted around $380 million in private investments since that time, while partnering with major players such as Gilead Sciences (Nasdaq: GILD), Amgen (Nasdaq: AMGN) and Roche (ROG: SIX) subsidiary Genentech.

With its focus on GLP-1 agonism, the Californian company could find itself at the epicenter of a revolution in the treatment of diabetes and obesity.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK